Detecting impaired glucose tolerance or type 2 diabetes mellitus by means of an oral glucose tolerance test in HIV-infected patients

HIV Medicine

Volumn 12, Issue 2, 2011, Pages 109-117

  Gianotti, N ^a   Visco, F ^a   Galli, L ^a   Barda, B ^a   Piatti, P ^b,c   Salpietro, S ^a   Bigoloni, A ^a   Vinci, C ^a   Nozza, S ^a   Gallotta, G ^a   Lazzarin, A ^a,c   Castagna, A ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Metabolic and Cardiovascular Division   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Antiretroviral therapy; Diabetes; HIV; Insulin resistance; Oral glucose tolerance test

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EXPOSURE; FEMALE; GLUCOSE BLOOD LEVEL; HEPATITIS B; HEPATITIS C; HOMEOSTATIC MODEL ASSESSMENT FOR INSULIN RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPAIRED GLUCOSE TOLERANCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RISK FACTOR; SCREENING TEST; VIRUS LOAD;

ADULT; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HIV INFECTIONS; HIV-1; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED;

EID: 79954594423     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00860.x     Document Type: Article

References (42)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009; 32 (Suppl 1): S62-S67.
2. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
3. Walli R, Herfort O, Michl GM et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998; 12: F167-F173.
4. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093-2099.
5. Brambilla AM, Novati R, Calori G et al. Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals. AIDS 2003; 17: 1993-1995.
6. Tien PC, Schneider MF, Cole SR et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS 2007; 21: 1739-1745.
7. Ledergerber B, Furrer H, Rickenbach M et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis 2007; 45: 111-119.
8. De Wit S, Sabin CA, Weber R et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008; 31: 1224-1229.
9. Lo YC, Chen MY, Sheng WH et al. Risk factors for incident diabetes mellitus among HIV-infected patients receiving combination antiretroviral therapy in Taiwan: a case-control study. HIV Med 2009; 10: 302-309.
10. Butt AA, McGinnis K, Rodriguez-Barradas MC et al. HIV infection and the risk of diabetes mellitus. AIDS 2009; 23: 1227-1234.
11. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D for the Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 2479-2486.
12. Friis-Moller N, Reiss P, Sabin CA et al. for the DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-1735.
13. Sabin CA, Worm SW, Weber R et al. for the D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371: 1417-1426.
14. SMART/INSIGHT, DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22: F17-F24.
15. Phillips AN, Carr A, Neuhaus J et al. Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther 2008; 13: 177-187.
16. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30: 471-477.
17. Currier JS, Taylor A, Boyd F et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33: 506-512.
18. Friis-Moller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
19. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995; 18: 258-268.
20. Harris MI. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 1993; 16: 642-652.
21. Brown TT, Cole SR, Li X et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165: 1179-1184.
22. Kahn R, Buse J, Ferrannini E, Stern M for the American Diabetes Association & European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289-2304.
23. Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N, Grinspoon S. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999; 84: 1932-1937.
24. Hadigan C, Corcoran C, Stanley T, Piecuch S, Klibanski A, Grinspoon S. Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use. J Clin Endocrinol Metab 2000; 85: 35-41.
25. American Diabetes Association. Standards of medical care in diabetes - 2009. Diabetes Care 2009; 32 (Suppl 1): S13-S61.
26. Tabak AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimaki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 2009; 373: 2215-2221.
27. Howard AA, Floris-Moore M, Arnsten JH et al. Disorders of glucose metabolism among HIV-infected women. Clin Infect Dis 2005; 40: 1492-1499.
28. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
29. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
30. Schambelan M, Benson CA, Carr A et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002; 31: 257-275.
31. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med 2002; 346: 393-403.
32. Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
33. Samaras K. Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 50: 499-505.
34. Despres JP, Lamarche B, Mauriege P et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957.
35. Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Circulation 1998; 98: 398-404.
36. Wallace TM, Matthews DR. The assessment of insulin resistance in man. Diabet Med 2002; 19: 527-534.
37. Florescu D, Kotler DP. Insulin resistance, glucose intolerance and diabetes mellitus in HIV-infected patients. Antivir Ther 2007; 12: 149-162.
38. Justman JE, Benning L, Danoff A et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 2003; 32: 298-302.
39. Duong M, Petit JM, Piroth L et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27: 245-250.
40. Mehta SH, Moore RD, Thomas DL, Chaisson RE, Sulkowski MS. The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. J Acquir Immune Defic Syndr 2003; 33: 577-584.
41. de Larranaga GF, Wingeyer SD, Puga LM, Alonso BS, Benetucci JA. Relationship between hepatitis C virus (HCV) and insulin resistance, endothelial perturbation, and platelet activation in HIV-HCV-coinfected patients under highly active antiretroviral treatment. Eur J Clin Microbiol Infect Dis 2006; 25: 98-103.
42. Huang JF, Yu ML, Dai CY et al. Reappraisal of the characteristics of glucose abnormalities in patients with chronic hepatitis C infection. Am J Gastroenterol 2008; 103: 1933-1940.